Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks

Purpose: Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor of rapid disease progression and short remission duration in CLL. We conducted this study to advance our understanding of the causes of genom...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research Vol. 16; no. 3; pp. 835 - 847
Main Authors: OUILLETTE, Peter, FOSSUM, Samuel, PARKIN, Brian, LI DING, BOCKENSTEDT, Paula, AL-ZOUBI, Ammar, SHEDDEN, Kerby, MALEK, Sami N
Format: Journal Article
Language:English
Published: Philadelphia, PA American Association for Cancer Research 01-02-2010
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Purpose: Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor of rapid disease progression and short remission duration in CLL. We conducted this study to advance our understanding of the causes of genomic complexity in CLL. Experimental Design: We have obtained quantitative measurements of radiation-induced apoptosis and radiation-induced ATM autophosphorylation in purified CLL cells from 158 and 140 patients, respectively, and have used multivariate analysis to identify independent contributions of various biological variables on genomic complexity in CLL. Results: Here, we identify a strong independent effect of radiation resistance on elevated genomic complexity in CLL and describe radiation resistance as a predictor for shortened CLL survival. Furthermore, using multivariate analysis, we identify del17p/p53 aberrations, del11q, del13q14 type II (invariably resulting in Rb loss), and CD38 expression as independent predictors of genomic complexity in CLL, with aberrant p53 as a predictor of ∼50% of genomic complexity in CLL. Focusing on del11q, we determined that normalized ATM activity was a modest predictor of genomic complexity but was not independent of del11q. Through single nucleotide polymorphism array–based fine mapping of del11q, we identified frequent monoallelic loss of Mre11 and H2AFX in addition to ATM , indicative of compound del11q–resident gene defects in the DNA double-strand break response. Conclusions: Our quantitative analysis links multiple molecular defects, including for the first time del11q and large 13q14 deletions (type II), to elevated genomic complexity in CLL, thereby suggesting mechanisms for the observed clinical aggressiveness of CLL in patients with unstable genomes. Clin Cancer Res; 16(3); 835–47
AbstractList Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor of rapid disease progression and short remission duration in CLL. We conducted this study to advance our understanding of the causes of genomic complexity in CLL. We have obtained quantitative measurements of radiation-induced apoptosis and radiation-induced ATM autophosphorylation in purified CLL cells from 158 and 140 patients, respectively, and have used multivariate analysis to identify independent contributions of various biological variables on genomic complexity in CLL. Here, we identify a strong independent effect of radiation resistance on elevated genomic complexity in CLL and describe radiation resistance as a predictor for shortened CLL survival. Furthermore, using multivariate analysis, we identify del17p/p53 aberrations, del11q, del13q14 type II (invariably resulting in Rb loss), and CD38 expression as independent predictors of genomic complexity in CLL, with aberrant p53 as a predictor of approximately 50% of genomic complexity in CLL. Focusing on del11q, we determined that normalized ATM activity was a modest predictor of genomic complexity but was not independent of del11q. Through single nucleotide polymorphism array-based fine mapping of del11q, we identified frequent monoallelic loss of Mre11 and H2AFX in addition to ATM, indicative of compound del11q-resident gene defects in the DNA double-strand break response. Our quantitative analysis links multiple molecular defects, including for the first time del11q and large 13q14 deletions (type II), to elevated genomic complexity in CLL, thereby suggesting mechanisms for the observed clinical aggressiveness of CLL in patients with unstable genomes.
Purpose: Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor of rapid disease progression and short remission duration in CLL. We conducted this study to advance our understanding of the causes of genomic complexity in CLL. Experimental Design: We have obtained quantitative measurements of radiation-induced apoptosis and radiation-induced ATM autophosphorylation in purified CLL cells from 158 and 140 patients, respectively, and have used multivariate analysis to identify independent contributions of various biological variables on genomic complexity in CLL. Results: Here, we identify a strong independent effect of radiation resistance on elevated genomic complexity in CLL and describe radiation resistance as a predictor for shortened CLL survival. Furthermore, using multivariate analysis, we identify del17p/p53 aberrations, del11q, del13q14 type II (invariably resulting in Rb loss), and CD38 expression as independent predictors of genomic complexity in CLL, with aberrant p53 as a predictor of ∼50% of genomic complexity in CLL. Focusing on del11q, we determined that normalized ATM activity was a modest predictor of genomic complexity but was not independent of del11q. Through single nucleotide polymorphism array–based fine mapping of del11q, we identified frequent monoallelic loss of Mre11 and H2AFX in addition to ATM , indicative of compound del11q–resident gene defects in the DNA double-strand break response. Conclusions: Our quantitative analysis links multiple molecular defects, including for the first time del11q and large 13q14 deletions (type II), to elevated genomic complexity in CLL, thereby suggesting mechanisms for the observed clinical aggressiveness of CLL in patients with unstable genomes. Clin Cancer Res; 16(3); 835–47
Purpose: Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor of rapid disease progression and short remission duration in CLL. We conducted this study to advance our understanding of the causes of genomic complexity in CLL. Experimental Design: We have obtained quantitative measurements of radiation-induced apoptosis and radiation-induced ATM autophosphorylation in purified CLL cells from 158 and 140 patients, respectively, and have used multivariate analysis to identify independent contributions of various biological variables on genomic complexity in CLL. Results: Here, we identify a strong independent effect of radiation resistance on elevated genomic complexity in CLL and describe radiation resistance as a predictor for shortened CLL survival. Furthermore, using multivariate analysis, we identify del17p/p53 aberrations, del11q, del13q14 type II (invariably resulting in Rb loss), and CD38 expression as independent predictors of genomic complexity in CLL, with aberrant p53 as a predictor of ∼50% of genomic complexity in CLL. Focusing on del11q, we determined that normalized ATM activity was a modest predictor of genomic complexity but was not independent of del11q. Through single nucleotide polymorphism array–based fine mapping of del11q, we identified frequent monoallelic loss of Mre11 and H2AFX in addition to ATM, indicative of compound del11q–resident gene defects in the DNA double-strand break response. Conclusions: Our quantitative analysis links multiple molecular defects, including for the first time del11q and large 13q14 deletions (type II), to elevated genomic complexity in CLL, thereby suggesting mechanisms for the observed clinical aggressiveness of CLL in patients with unstable genomes. Clin Cancer Res; 16(3); 835–47
Author Peter Ouillette
Samuel Fossum
Brian Parkin
Ammar Al-Zoubi
Li Ding
Paula Bockenstedt
Sami N. Malek
Kerby Shedden
AuthorAffiliation 1 Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA
2 Department of Statistics, University of Michigan, Ann Arbor, MI, USA
AuthorAffiliation_xml – name: 2 Department of Statistics, University of Michigan, Ann Arbor, MI, USA
– name: 1 Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA
Author_xml – sequence: 1
  givenname: Peter
  surname: OUILLETTE
  fullname: OUILLETTE, Peter
  organization: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
– sequence: 2
  givenname: Samuel
  surname: FOSSUM
  fullname: FOSSUM, Samuel
  organization: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
– sequence: 3
  givenname: Brian
  surname: PARKIN
  fullname: PARKIN, Brian
  organization: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
– sequence: 4
  surname: LI DING
  fullname: LI DING
  organization: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
– sequence: 5
  givenname: Paula
  surname: BOCKENSTEDT
  fullname: BOCKENSTEDT, Paula
  organization: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
– sequence: 6
  givenname: Ammar
  surname: AL-ZOUBI
  fullname: AL-ZOUBI, Ammar
  organization: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
– sequence: 7
  givenname: Kerby
  surname: SHEDDEN
  fullname: SHEDDEN, Kerby
  organization: Department of Statistics, University of Michigan, Ann Arbor, Michigan, United States
– sequence: 8
  givenname: Sami N
  surname: MALEK
  fullname: MALEK, Sami N
  organization: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22447420$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20086003$$D View this record in MEDLINE/PubMed
BookMark eNpVkdtu1DAQhi1URA_wCCDfIK5SfIqTvUHaZkuptIBU4NpynMnGNIkj27tlH4Z3xem2Ba480v_NeOzvFB2NbgSEXlNyTmlevqekKDMiODuvqpuMLDKWc_EMndA8LzLOZH6U6kfmGJ2G8JMQKigRL9AxI6SUhPAT9Hu52XgIwe4AV513ozV4vR-mzpl9nGvY3sJgNb6zscOXPex0hAZfweiGFFdumHr4ZeMeXwe8DMEZew_c45-3fbQpn3HAK2jBxIDtiGMH-AbC5MYAODq8-rLEK7ete8i-Ra_HBl940LfhJXre6j7Aq4fzDP34ePm9-pStv15dV8t1ZkTBYtbIumzzQjZUNrzIjWxZKziVgjLZGgY5AUN10xgiU0oYKWpS1jUTQjYLsdD8DH04zJ229QCNgTFt0avJ20H7vXLaqv-T0XZq43aKlbSUkqcB-WGA8S4ED-1TLyVq9qVmF2p2oZIvRRZq9pX63vx78VPXo6AEvH0AdDC6b9PnGBv-cukNhWAkce8OXGc33Z31oEwiwSe3oL3pFJWKq5Ln_A_B07EW
CODEN CCREF4
CitedBy_id crossref_primary_10_1002_gcc_21997
crossref_primary_10_1038_jhg_2015_166
crossref_primary_10_1038_onc_2012_411
crossref_primary_10_1111_bjh_15421
crossref_primary_10_1182_blood_2012_09_458265
crossref_primary_10_1007_s12185_019_02788_7
crossref_primary_10_1038_leu_2010_288
crossref_primary_10_1186_s13039_017_0353_1
crossref_primary_10_1371_journal_pone_0066361
crossref_primary_10_3960_jslrt_20036
crossref_primary_10_1146_annurev_pathmechdis_012419_032810
crossref_primary_10_1016_j_exphem_2011_11_005
crossref_primary_10_1016_j_ijscr_2023_108748
crossref_primary_10_1038_nrc_2016_8
crossref_primary_10_1038_leu_2016_134
crossref_primary_10_1182_asheducation_2010_1_70
crossref_primary_10_1200_JCO_2011_41_0852
crossref_primary_10_1182_asheducation_2014_1_119
crossref_primary_10_3109_10428194_2012_702902
crossref_primary_10_1002_ajh_23978
crossref_primary_10_1016_j_pathol_2022_12_354
crossref_primary_10_1042_BCJ20160256
crossref_primary_10_5045_br_2020_2020080
crossref_primary_10_1017_erm_2020_3
crossref_primary_10_1155_2014_435983
crossref_primary_10_3109_10428194_2013_829919
crossref_primary_10_1111_cas_13859
crossref_primary_10_1111_bjh_13254
crossref_primary_10_1002_humu_22057
crossref_primary_10_1111_j_1365_2141_2011_09022_x
crossref_primary_10_1182_bloodadvances_2020003726
crossref_primary_10_1182_blood_2010_12_327858
crossref_primary_10_1080_10428194_2018_1498494
crossref_primary_10_1053_j_seminoncol_2016_02_002
crossref_primary_10_1002_ajh_23545
crossref_primary_10_1158_1078_0432_CCR_11_2342
crossref_primary_10_1159_000443820
crossref_primary_10_3389_fgene_2015_00207
crossref_primary_10_1038_leu_2014_297
crossref_primary_10_1038_leu_2016_10
crossref_primary_10_1371_journal_pone_0100950
crossref_primary_10_1038_s41375_020_0714_3
crossref_primary_10_1016_j_anndiagpath_2010_08_003
crossref_primary_10_1084_jem_20131448
crossref_primary_10_1158_1078_0432_CCR_11_0785
crossref_primary_10_1182_bloodadvances_2017015560
crossref_primary_10_1155_2014_106713
crossref_primary_10_1158_1078_0432_CCR_10_2058
Cites_doi 10.1200/JCO.2006.06.9492
10.1038/nature02820
10.1080/09553000110120364
10.1038/sj.leu.2404935
10.1038/sj.leu.2404120
10.1016/j.cell.2004.11.022
10.1038/sj.onc.1210880
10.1182/blood-2004-07-2713
10.1182/blood-2008-04-154070
10.1182/blood.V98.9.2633
10.1182/blood-2001-11-0066
10.1038/ng1861
10.1182/blood-2002-06-1683
10.1038/leu.2008.274
10.1182/blood-2006-05-020735
10.1182/blood.V94.6.1848
10.1182/blood-2003-09-3236
10.1182/blood-2004-07-2888
10.1016/S0092-8674(03)00566-X
10.1182/blood.V100.4.1410.h81602001410_1410_1416
10.1158/0008-5472.CAN-07-3105
10.1182/blood-2002-10-3306
10.1111/j.1600-0609.2008.01177.x
10.1182/blood.V100.4.1177.h81602001177_1177_1184
10.1182/blood-2008-01-129726
10.1182/blood.V84.9.3148.3148
10.1038/sj.leu.2404764
10.1200/JCO.2008.16.7874
10.1056/NEJMoa040857
10.1126/science.2565047
10.1159/000167821
10.1182/blood-2007-07-099432
10.1200/JCO.2007.11.2649
10.1016/j.cell.2008.08.015
10.1182/blood-2005-05-2093
10.1038/sj.onc.1207318
10.1016/S0140-6736(03)15260-9
10.1016/j.cell.2007.06.016
10.1038/nature01368
10.1073/pnas.0803520105
10.1056/NEJM200012283432602
10.1182/blood.V98.3.814
10.1182/blood-2004-11-4516
10.1182/blood-2007-09-112698
10.1182/blood.V94.6.1840
10.1182/blood.V98.1.181
10.1200/JCO.2006.08.3089
10.1056/NEJMoa023143
10.1182/blood-2006-02-005322
ContentType Journal Article
Copyright 2015 INIST-CNRS
Copyright_xml – notice: 2015 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
DOI 10.1158/1078-0432.CCR-09-2534
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE

CrossRef
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 847
ExternalDocumentID 10_1158_1078_0432_CCR_09_2534
20086003
22447420
16_3_835
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: 1 R21 CA124420-01A1
– fundername: NCI NIH HHS
  grantid: R21 CA124420-02
– fundername: NCI NIH HHS
  grantid: 1R01 CA136537-01
– fundername: NCI NIH HHS
  grantid: 5 P30 CA46592
– fundername: NCI NIH HHS
  grantid: R01 CA136537-01A1
– fundername: NCI NIH HHS
  grantid: P30 CA046592
– fundername: NCI NIH HHS
  grantid: R01 CA136537
– fundername: NCI NIH HHS
  grantid: R21 CA124420-01A1
– fundername: NCI NIH HHS
  grantid: R21 CA124420
GroupedDBID -
29B
2WC
34G
39C
3O-
4H-
53G
5GY
5RE
5VS
AAPBV
ABFLS
ABOCM
ACIWK
ACPRK
ADACO
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
GX1
H13
IH2
KQ8
L7B
LSO
O0-
OK1
P0W
P2P
RCR
RHF
RHI
RNS
SJN
UDS
W2D
WOQ
ZA5
---
.55
.GJ
08R
18M
1CY
2FS
476
6J9
AAUGY
ACGFO
ACSVP
ADCOW
ADNWM
AETEA
AFHIN
AFOSN
AI.
BR6
BTFSW
H~9
IQODW
J5H
MVM
OHT
QTD
TR2
VH1
W8F
WHG
X7M
XFK
XJT
YKV
ZCG
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
ID FETCH-LOGICAL-c472t-d6b8f576d16d375c6f2f43164126fc2e50ec1addc0675c0207b08bb2446d949a3
ISSN 1078-0432
IngestDate Tue Sep 17 21:28:21 EDT 2024
Thu Nov 21 21:03:01 EST 2024
Sat Sep 28 07:59:43 EDT 2024
Sun Oct 29 17:09:04 EDT 2023
Fri Jan 15 19:22:25 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Double stranded DNA
Chronic lymphocytic leukemia
Lymphoproliferative syndrome
Genomics
Genetics
Malignant hemopathy
Mutation
Genome
Cancer
Complexity
High malignancy
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c472t-d6b8f576d16d375c6f2f43164126fc2e50ec1addc0675c0207b08bb2446d949a3
OpenAccessLink https://aacrjournals.org/clincancerres/article-pdf/16/3/835/1994158/835.pdf
PMID 20086003
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2818663
crossref_primary_10_1158_1078_0432_CCR_09_2534
pubmed_primary_20086003
pascalfrancis_primary_22447420
highwire_cancerresearch_16_3_835
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 2010-02-01
PublicationDateYYYYMMDD 2010-02-01
PublicationDate_xml – month: 02
  year: 2010
  text: 2010-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2010
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 18281475 - Cancer Res. 2008 Feb 15;68(4):1012-21
12149224 - Blood. 2002 Aug 15;100(4):1404-9
12149225 - Blood. 2002 Aug 15;100(4):1410-6
15329427 - N Engl J Med. 2004 Aug 26;351(9):893-901
15138159 - Blood. 2004 Sep 1;104(5):1428-34
11675331 - Blood. 2001 Nov 1;98(9):2633-9
18854157 - Cell. 2008 Oct 3;135(1):85-96
17003373 - Blood. 2007 Jan 15;109(2):399-404
18436738 - Blood. 2008 Sep 1;112(5):1993-2003
11136261 - N Engl J Med. 2000 Dec 28;343(26):1910-6
7949187 - Blood. 1994 Nov 1;84(9):3148-57
18689542 - Blood. 2008 Oct 15;112(8):3322-9
10477712 - Blood. 1999 Sep 15;94(6):1840-7
16840733 - Blood. 2006 Nov 1;108(9):3152-60
18843282 - Leukemia. 2009 Jan;23(1):117-24
10477713 - Blood. 1999 Sep 15;94(6):1848-54
12194750 - Int J Radiat Biol. 2002 Aug;78(8):671-9
18066087 - Oncogene. 2007 Dec 10;26(56):7749-58
12595313 - Blood. 2003 Jun 15;101(12):4944-51
11468183 - Blood. 2001 Aug 1;98(3):814-22
15550242 - Cell. 2004 Nov 24;119(5):591-602
16014569 - Blood. 2005 Nov 1;106(9):3175-82
18424664 - Blood. 2008 Jun 15;111(12):5646-53
14755251 - Oncogene. 2004 Mar 11;23(10):1911-21
9788599 - Cancer Res. 1998 Oct 15;58(20):4552-7
18599436 - Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9302-6
16921376 - Nat Genet. 2006 Sep;38(9):1043-8
12724482 - N Engl J Med. 2003 May 1;348(18):1764-75
2565047 - Science. 1989 Apr 14;244(4901):207-11
16437137 - Leukemia. 2006 Apr;20(4):737-40
12914700 - Cell. 2003 Aug 8;114(3):359-70
12556884 - Nature. 2003 Jan 30;421(6922):499-506
17971485 - Blood. 2008 Feb 1;111(3):1584-93
18467710 - J Clin Oncol. 2008 May 10;26(14):e5-6
16179374 - Blood. 2006 Jan 15;107(2):742-51
19018867 - Eur J Haematol. 2009 Feb;82(2):133-42
17283363 - J Clin Oncol. 2007 Mar 1;25(7):799-804
15692065 - Blood. 2005 Jun 1;105(11):4484-91
19188704 - Cytogenet Genome Res. 2008;122(3-4):343-9
15306814 - Nature. 2004 Aug 12;430(7001):797-802
17805327 - Leukemia. 2007 Dec;21(12):2442-51
15718417 - Blood. 2005 Jun 15;105(12):4776-83
17968022 - J Clin Oncol. 2007 Dec 1;25(34):5448-57
17008705 - J Clin Oncol. 2006 Oct 1;24(28):4634-41
12393534 - Blood. 2002 Dec 15;100(13):4609-14
17541398 - Leukemia. 2007 Aug;21(8):1715-22
11418478 - Blood. 2001 Jul 1;98(1):181-6
17599403 - Cell. 2007 Jul 13;130(1):63-75
14726163 - Lancet. 2004 Jan 10;363(9403):105-11
12149195 - Blood. 2002 Aug 15;100(4):1177-84
Krober (2022061023012781600_bib26) 2002; 100
Jones (2022061023012781600_bib43) 2004; 23
Orchard (2022061023012781600_bib30) 2004; 363
Bassing (2022061023012781600_bib47) 2003; 114
Starostik (2022061023012781600_bib15) 1998; 58
Aydin (2022061023012781600_bib50) 2008; 111
Oscier (2022061023012781600_bib28) 2002; 100
Rassenti (2022061023012781600_bib22) 2004; 351
Callen (2022061023012781600_bib46) 2007; 130
Wattel (2022061023012781600_bib40) 1994; 84
Buis (2022061023012781600_bib44) 2008; 135
Deriano (2022061023012781600_bib39) 2005
Del Poeta (2022061023012781600_bib23) 2001; 98
Hernando (2022061023012781600_bib49) 2004; 430
Zenz (2022061023012781600_bib13) 2008; 112
Austen (2022061023012781600_bib10) 2007; 25
Carter (2022061023012781600_bib48) 2006; 20
Bond (2022061023012781600_bib33) 2004; 119
Lin (2022061023012781600_bib27) 2002; 100
Dicker (2022061023012781600_bib9) 2006; 108
Austen (2022061023012781600_bib11) 2005; 106
Byrd (2022061023012781600_bib17) 2007; 109
Pettitt (2022061023012781600_bib36) 2001; 98
Mayr (2022061023012781600_bib4) 2006; 107
Shanafelt (2022061023012781600_bib2) 2006; 24
Grever (2022061023012781600_bib3) 2007; 25
Wiestner (2022061023012781600_bib21) 2003; 101
Van Den Neste (2022061023012781600_bib7) 2007; 21
Cejkova (2022061023012781600_bib42) 2009; 82
Chen (2022061023012781600_bib25) 2002; 100
Vogelstein (2022061023012781600_bib34) 1989; 244
Damle (2022061023012781600_bib20) 1999; 94
Ouillette (2022061023012781600_bib32) 2008; 68
Lavin (2022061023012781600_bib31) 2007; 26
Salin (2022061023012781600_bib38) 2008; 122
Alvi (2022061023012781600_bib18) 2005; 105
Saddler (2022061023012781600_bib12) 2008; 111
Bakkenist (2022061023012781600_bib41) 2003; 421
Hamblin (2022061023012781600_bib19) 1999; 94
Zha (2022061023012781600_bib45) 2008; 105
Rosenwald (2022061023012781600_bib16) 2004; 104
Dicker (2022061023012781600_bib14) 2009; 23
Crespo (2022061023012781600_bib29) 2003; 348
Blaise (2022061023012781600_bib37) 2002; 78
Kujawski (2022061023012781600_bib6) 2008; 112
Haferlach (2022061023012781600_bib8) 2007; 21
Dohner (2022061023012781600_bib1) 2000; 343
Carter (2022061023012781600_bib35) 2006; 38
Ibrahim (2022061023012781600_bib24) 2001; 98
Shanafelt (2022061023012781600_bib5) 2008; 26
References_xml – volume: 24
  start-page: 4634
  year: 2006
  ident: 2022061023012781600_bib2
  article-title: Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.06.9492
  contributor:
    fullname: Shanafelt
– volume: 430
  start-page: 797
  year: 2004
  ident: 2022061023012781600_bib49
  article-title: Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control
  publication-title: Nature
  doi: 10.1038/nature02820
  contributor:
    fullname: Hernando
– volume: 58
  start-page: 4552
  year: 1998
  ident: 2022061023012781600_bib15
  article-title: Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia
  publication-title: Cancer Res
  contributor:
    fullname: Starostik
– volume: 78
  start-page: 671
  year: 2002
  ident: 2022061023012781600_bib37
  article-title: High levels of chromosome aberrations correlate with impaired in vitro radiation-induced apoptosis and DNA repair in human B-chronic lymphocytic leukaemia cells
  publication-title: Int J Radiat Biol
  doi: 10.1080/09553000110120364
  contributor:
    fullname: Blaise
– volume: 21
  start-page: 2442
  year: 2007
  ident: 2022061023012781600_bib8
  article-title: Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404935
  contributor:
    fullname: Haferlach
– volume: 20
  start-page: 737
  year: 2006
  ident: 2022061023012781600_bib48
  article-title: Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404120
  contributor:
    fullname: Carter
– volume: 119
  start-page: 591
  year: 2004
  ident: 2022061023012781600_bib33
  article-title: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
  publication-title: Cell
  doi: 10.1016/j.cell.2004.11.022
  contributor:
    fullname: Bond
– volume: 26
  start-page: 7749
  year: 2007
  ident: 2022061023012781600_bib31
  article-title: ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210880
  contributor:
    fullname: Lavin
– volume: 105
  start-page: 4484
  year: 2005
  ident: 2022061023012781600_bib18
  article-title: A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2713
  contributor:
    fullname: Alvi
– volume: 112
  start-page: 3322
  year: 2008
  ident: 2022061023012781600_bib13
  article-title: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
  publication-title: Blood
  doi: 10.1182/blood-2008-04-154070
  contributor:
    fullname: Zenz
– volume: 98
  start-page: 2633
  year: 2001
  ident: 2022061023012781600_bib23
  article-title: Clinical significance of CD38 expression in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V98.9.2633
  contributor:
    fullname: Del Poeta
– volume: 100
  start-page: 1404
  year: 2002
  ident: 2022061023012781600_bib27
  article-title: Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2001-11-0066
  contributor:
    fullname: Lin
– volume: 38
  start-page: 1043
  year: 2006
  ident: 2022061023012781600_bib35
  article-title: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers [see comment]
  publication-title: Nat Genet
  doi: 10.1038/ng1861
  contributor:
    fullname: Carter
– volume: 100
  start-page: 4609
  year: 2002
  ident: 2022061023012781600_bib25
  article-title: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2002-06-1683
  contributor:
    fullname: Chen
– volume: 23
  start-page: 117
  year: 2009
  ident: 2022061023012781600_bib14
  article-title: The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
  publication-title: Leukemia
  doi: 10.1038/leu.2008.274
  contributor:
    fullname: Dicker
– volume: 109
  start-page: 399
  year: 2007
  ident: 2022061023012781600_bib17
  article-title: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2006-05-020735
  contributor:
    fullname: Byrd
– volume: 94
  start-page: 1848
  year: 1999
  ident: 2022061023012781600_bib19
  article-title: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V94.6.1848
  contributor:
    fullname: Hamblin
– volume: 104
  start-page: 1428
  year: 2004
  ident: 2022061023012781600_bib16
  article-title: Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
  publication-title: Blood
  doi: 10.1182/blood-2003-09-3236
  contributor:
    fullname: Rosenwald
– year: 2005
  ident: 2022061023012781600_bib39
  article-title: Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the non-homologous end-joining DNA repair pathway
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2888
  contributor:
    fullname: Deriano
– volume: 114
  start-page: 359
  year: 2003
  ident: 2022061023012781600_bib47
  article-title: Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)00566-X
  contributor:
    fullname: Bassing
– volume: 100
  start-page: 1410
  year: 2002
  ident: 2022061023012781600_bib26
  article-title: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V100.4.1410.h81602001410_1410_1416
  contributor:
    fullname: Krober
– volume: 68
  start-page: 1012
  year: 2008
  ident: 2022061023012781600_bib32
  article-title: Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-3105
  contributor:
    fullname: Ouillette
– volume: 101
  start-page: 4944
  year: 2003
  ident: 2022061023012781600_bib21
  article-title: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
  publication-title: Blood
  doi: 10.1182/blood-2002-10-3306
  contributor:
    fullname: Wiestner
– volume: 82
  start-page: 133
  year: 2009
  ident: 2022061023012781600_bib42
  article-title: Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine
  publication-title: Eur J Haematol
  doi: 10.1111/j.1600-0609.2008.01177.x
  contributor:
    fullname: Cejkova
– volume: 100
  start-page: 1177
  year: 2002
  ident: 2022061023012781600_bib28
  article-title: Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors
  publication-title: Blood
  doi: 10.1182/blood.V100.4.1177.h81602001177_1177_1184
  contributor:
    fullname: Oscier
– volume: 111
  start-page: 5646
  year: 2008
  ident: 2022061023012781600_bib50
  article-title: CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?
  publication-title: Blood
  doi: 10.1182/blood-2008-01-129726
  contributor:
    fullname: Aydin
– volume: 84
  start-page: 3148
  year: 1994
  ident: 2022061023012781600_bib40
  article-title: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
  publication-title: Blood
  doi: 10.1182/blood.V84.9.3148.3148
  contributor:
    fullname: Wattel
– volume: 21
  start-page: 1715
  year: 2007
  ident: 2022061023012781600_bib7
  article-title: Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404764
  contributor:
    fullname: Van Den Neste
– volume: 26
  start-page: e5
  year: 2008
  ident: 2022061023012781600_bib5
  article-title: Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.16.7874
  contributor:
    fullname: Shanafelt
– volume: 351
  start-page: 893
  year: 2004
  ident: 2022061023012781600_bib22
  article-title: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa040857
  contributor:
    fullname: Rassenti
– volume: 244
  start-page: 207
  year: 1989
  ident: 2022061023012781600_bib34
  article-title: Allelotype of colorectal carcinomas
  publication-title: Science (New York, NY)
  doi: 10.1126/science.2565047
  contributor:
    fullname: Vogelstein
– volume: 122
  start-page: 343
  year: 2008
  ident: 2022061023012781600_bib38
  article-title: Increased genomic alteration complexity and telomere shortening in B-CLL cells resistant to radiation-induced apoptosis
  publication-title: Cytogenet Genome Res
  doi: 10.1159/000167821
  contributor:
    fullname: Salin
– volume: 112
  start-page: 1993
  year: 2008
  ident: 2022061023012781600_bib6
  article-title: Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2007-07-099432
  contributor:
    fullname: Kujawski
– volume: 25
  start-page: 5448
  year: 2007
  ident: 2022061023012781600_bib10
  article-title: Mutation Status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.11.2649
  contributor:
    fullname: Austen
– volume: 135
  start-page: 85
  year: 2008
  ident: 2022061023012781600_bib44
  article-title: Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation
  publication-title: Cell
  doi: 10.1016/j.cell.2008.08.015
  contributor:
    fullname: Buis
– volume: 107
  start-page: 742
  year: 2006
  ident: 2022061023012781600_bib4
  article-title: Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2005-05-2093
  contributor:
    fullname: Mayr
– volume: 23
  start-page: 1911
  year: 2004
  ident: 2022061023012781600_bib43
  article-title: The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207318
  contributor:
    fullname: Jones
– volume: 363
  start-page: 105
  year: 2004
  ident: 2022061023012781600_bib30
  article-title: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)15260-9
  contributor:
    fullname: Orchard
– volume: 130
  start-page: 63
  year: 2007
  ident: 2022061023012781600_bib46
  article-title: ATM prevents the persistence and propagation of chromosome breaks in lymphocytes
  publication-title: Cell
  doi: 10.1016/j.cell.2007.06.016
  contributor:
    fullname: Callen
– volume: 421
  start-page: 499
  year: 2003
  ident: 2022061023012781600_bib41
  article-title: DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
  publication-title: Nature
  doi: 10.1038/nature01368
  contributor:
    fullname: Bakkenist
– volume: 105
  start-page: 9302
  year: 2008
  ident: 2022061023012781600_bib45
  article-title: Complementary functions of ATM and H2AX in development and suppression of genomic instability
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0803520105
  contributor:
    fullname: Zha
– volume: 343
  start-page: 1910
  year: 2000
  ident: 2022061023012781600_bib1
  article-title: Genomic aberrations and survival in chronic lymphocytic leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200012283432602
  contributor:
    fullname: Dohner
– volume: 98
  start-page: 814
  year: 2001
  ident: 2022061023012781600_bib36
  article-title: p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation
  publication-title: Blood
  doi: 10.1182/blood.V98.3.814
  contributor:
    fullname: Pettitt
– volume: 106
  start-page: 3175
  year: 2005
  ident: 2022061023012781600_bib11
  article-title: Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL
  publication-title: Blood
  doi: 10.1182/blood-2004-11-4516
  contributor:
    fullname: Austen
– volume: 111
  start-page: 1584
  year: 2008
  ident: 2022061023012781600_bib12
  article-title: Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2007-09-112698
  contributor:
    fullname: Saddler
– volume: 94
  start-page: 1840
  year: 1999
  ident: 2022061023012781600_bib20
  article-title: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V94.6.1840
  contributor:
    fullname: Damle
– volume: 98
  start-page: 181
  year: 2001
  ident: 2022061023012781600_bib24
  article-title: CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V98.1.181
  contributor:
    fullname: Ibrahim
– volume: 25
  start-page: 799
  year: 2007
  ident: 2022061023012781600_bib3
  article-title: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.3089
  contributor:
    fullname: Grever
– volume: 348
  start-page: 1764
  year: 2003
  ident: 2022061023012781600_bib29
  article-title: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa023143
  contributor:
    fullname: Crespo
– volume: 108
  start-page: 3152
  year: 2006
  ident: 2022061023012781600_bib9
  article-title: Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression
  publication-title: Blood
  doi: 10.1182/blood-2006-02-005322
  contributor:
    fullname: Dicker
SSID ssj0014104
Score 2.2902656
Snippet Purpose: Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor...
Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor of rapid...
Purpose: Genomic complexity is present in approximately 15% to 30% of all chronic lymphocytic leukemia (CLL) and has emerged as a strong independent predictor...
SourceID pubmedcentral
crossref
pubmed
pascalfrancis
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 835
SubjectTerms Antineoplastic agents
Apoptosis - radiation effects
Ataxia Telangiectasia Mutated Proteins
Biological and medical sciences
Cell Cycle Proteins - metabolism
Chromosome Deletion
Chromosomes, Human, Pair 11
Chromosomes, Human, Pair 13
CLL
DNA Breaks, Double-Stranded
DNA double-strand break response
DNA-Binding Proteins - metabolism
genomic complexity
Hematologic and hematopoietic diseases
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Mutation
Pharmacology. Drug treatments
Phosphorylation
Protein-Serine-Threonine Kinases - metabolism
Radiation Tolerance
Tumor Suppressor Proteins - metabolism
Title Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks
URI http://clincancerres.aacrjournals.org/content/16/3/835.abstract
https://www.ncbi.nlm.nih.gov/pubmed/20086003
https://pubmed.ncbi.nlm.nih.gov/PMC2818663
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb5tAEF45qVT1UvUd9xHtoTfklOeCjw5e2zQ2WAZHyQnxVHOIGzn2z-l_7Qy7vNQe2kq9IAQDi_b7dnZmmZ0h5HPBtMyyE3NU5HkCDopmjpIkA1fFNliRa2Wh5_hHdxHa_o0z5SYfDOrKjO21_4o0XAOscefsX6DdvBQuwDlgDkdAHY5_hPtkPsdO9a654i42gQ-9vLxdrReBexvhOd9eQdeDOvCihcKX_HoCukuZ86qcoeIGq_WS33jRreKFIuejVwlU4qvtMvLgPopzZcpn3I1wC3IVNwStrgM_5EoUKFN_MpoG20sQxaLM_lS53PDJVdg1hd16T2aGxNsrMu1QszwdHHGb4kGU7-uFEc9gYhflmcPk_lg0MSK4g1uWn993WD-VZVuWd90lDvw734SLCK2sYhpg0-irbdahp9HRwY7If_Lr3GA51TKFfNeF624w8EO3xGpqhxsP9xU5MDQE7EGjnSrr8ID1ytWrVIHGCXmig4pDDRt-9Zv_V6ZWFa5sGpN7x-ATvvz2AzAntWytbyDVSasxZjd5BFBKUW-lYzD1g3k71lH0gjyXbg2dCD6-JINi94o8XcnAjdfkR0tLKmlJO7SkNS0p8ozWtKSSlrSlJfVC2tJSiNe0RHFOJS2p51OgJa1pSaOAtrSkgpZU0PIN2c545C5GsjLIKDNt_TDKWeqU4CnnGssN28pYqZeY08HUdFZmemGpRabBzJ2hP5yBR2SnqpOmYMqyfGyOE-MtOd193xVnhKq5WrJEzVmWgfPO9BQLFKS5Y5VjozAMNiQXNRzxg0gAE1eOs-XECGWMUMYAZayOY4RySGgNWiwGUD1-Yo3FRgz0HJLzHpjNi8GeNm1TV4fknQC1vSPZMSR2D-5GANPE9-_s7r5V6eIlU9__85MfyLN2VH4kp4f9sfhETh7z43nF-p90EcWX
link.rule.ids 230,315,782,786,887,27933,27934
linkProvider Multiple Vendors
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AGGRESSIVE+CHRONIC+LYMPHOCYTIC+LEUKEMIA+WITH+ELEVATED+GENOMIC+COMPLEXITY+IS+ASSOCIATED+WITH+MULTIPLE+GENE+DEFECTS+IN+THE+RESPONSE+TO+DNA-DOUBLE+STRAND+BREAKS&rft.jtitle=Clinical+cancer+research&rft.au=Ouillette%2C+Peter&rft.au=Fossum%2C+Samuel&rft.au=Parkin%2C+Brian&rft.au=Ding%2C+Li&rft.date=2010-02-01&rft.issn=1078-0432&rft.volume=16&rft.issue=3&rft.spage=835&rft_id=info:doi/10.1158%2F1078-0432.CCR-09-2534&rft_id=info%3Apmid%2F20086003&rft.externalDBID=PMC2818663
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon